| Primary hypogonadism
AndroGel vs Jatenzo
Side-by-side clinical, coverage, and cost comparison for primary hypogonadism.Deep comparison between: Androgel vs Jatenzo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJatenzo has a higher rate of injection site reactions vs Androgel based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Jatenzo but not Androgel, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Androgel
Jatenzo
At A Glance
Topical
Daily
Androgen
Oral
Twice daily
Androgen
Indications
- Primary hypogonadism
- Hypogonadotropic hypogonadism
- Primary hypogonadism
- Hypogonadotropic hypogonadism
Dosing
Primary hypogonadism, Hypogonadotropic hypogonadism Starting dose 40.5 mg testosterone (2 pump actuations or one 40.5 mg packet) applied once daily to upper arms and shoulders; titrate between 20.25 mg and 81 mg based on pre-dose morning serum testosterone at days 14 and 28 after starting or adjusting dose.
Primary hypogonadism, Hypogonadotropic hypogonadism Starting dose 237 mg orally twice daily (morning and evening) with food; dose adjusted between 158 mg and 396 mg twice daily based on serum testosterone concentration measured 6 hours after the morning dose.
Contraindications
- Carcinoma of the breast
- Known or suspected carcinoma of the prostate
- Pregnancy (can cause virilization of the female fetus)
- Carcinoma of the breast or known or suspected carcinoma of the prostate
- Pregnancy
- Known hypersensitivity to JATENZO or any of its ingredients
Adverse Reactions
Most common (>=5%) PSA increased
Serious Nonfatal arrhythmias warranting intervention, atrial fibrillation, acute kidney injury, bone fracture
Postmarketing Myocardial infarction, stroke, polycythemia, prostate cancer, venous thromboembolism, sleep apnea, priapism, gynecomastia
Most common (>=2%) Headache, hematocrit increased, hypertension, HDL decreased, nausea
Postmarketing Myocardial infarction, stroke, venous thromboembolism
Pharmacology
Endogenous androgen replacement; testosterone and dihydrotestosterone (DHT) are responsible for normal growth and development of male sex organs and maintenance of secondary sex characteristics, with male hypogonadism resulting from insufficient testosterone secretion due to gonadal defects (primary) or hypothalamic/pituitary failure (hypogonadotropic).
Testosterone undecanoate is a prodrug ester of testosterone; after oral absorption via intestinal lymphatics, endogenous esterases cleave the ester bond to release active testosterone, which binds androgen receptors to support normal male sexual development and maintenance of secondary sex characteristics.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Androgel
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Jatenzo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (10/12)
UnitedHealthcare
Androgel
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (0/8)
Jatenzo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Androgel
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Jatenzo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Androgel.
No savings programs available for Jatenzo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AndrogelView full Androgel profile
JatenzoView full Jatenzo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.